Schrodinger Inc. (NASDAQ: SDGR) reported Q2 EPS of ($0.65), $0.15 better than the analyst estimate of ($0.80). Revenue for the quarter came in at $54.8 million versus the consensus estimate of $52.02 million.

2025 Financial Outlook

As of August 6, 2025, Schrödinger updated its expectation for operating expenses and reaffirmed the other aspects of its previously issued financial guidance for the fiscal year ending December 31, 2025:

Software revenue growth is expected to range from 10% to 15%.
Drug discovery revenue is expected to range from $45 million to $50 million.
Software gross margin is expected to range from 74% to 75%.
Operating expenses in 2025 are now expected to be lower than 2024.
Cash used for operating activities in 2025 is expected to be significantly lower than cash used for operating activities in 2024.

For earnings history and earnings-related data on Schrodinger Inc. (SDGR) click here.